Sustained ventricular tachycardia induced by dobutamine stress echocardiography: A prospective study

Abstract

Sustained monomorphic VT is a rare complication of DSE, with no predictive value for the identification of patients with coronary artery disease and no prognostic significance in patients with normal coronary arteries. No predictors of its occurrence were identified.

Stress echocardiography: safety and tolerability

“…The clinical significance of Dobutamine stress echo induced ventricular tachycardia has not been clarified. Previous studies [5-7] failed to establish a relationship between this ventricular rhythm disturbance and inductile myocardial ischemia. Elhendy et al [8], in a series of 286 patients who underwent dobutamine stress echo and subsequent coronary angiography, reported that tachyarrhythmia during dobutamine stress were not predicted by the presence or the extent of coronary artery disease on angiography nor by the induction of ischemia during the stress echo.…”

Recovery from severe heart failure following peripartum cardiomyopathy

“…The remarkable ability of the PPCM heart to recover function lends hope to both patients and physicians that effective treatment may yield good results with time. In the recovered patient, as defined, it may be advisable to conduct an exercise stress echocardiography to assess contractile reserve; and particularly so if one is attempting to determine the relapse risk of HF in a subsequent pregnancy [12][13][14][15].…”

Feasibility and echocardiographic characteristics of a three-minute stage dobutamine stress test in healthy dogs

“…The most common cardiac adverse effects of DST in humans are ischemia and benign arrhythmias (isolated premature atrial or ventricular complexes) (Mertes et al, 1993). In contrast, life-threatening arrhythmias, such as sustained ventricular tachycardia and ventricular fibrillation, are rare complications of DSE (Lima et al, 2008;Katritsis et al, 2005;Mertes et al, 1993). Noncardiac adverse effects of DST in humans are nausea, anxiety, headache, dizziness, tremor, dyspnea and urgency (SanRoman et al, 2003;Lu et al, 2001;Mertes et al, 1993).…”

“…However, no standardized dobutamine stress test (DST) exists in human medicine, and safety, feasibility and diagnostic accuracy of different protocols were reported. These protocols vary from 3-minute to 5-minute stage duration (Katritsis et al, 2005;Kamaran et al, 1995) and from a low dose (5 or 10 µg/kg/min) (Schinkel et al, 2004) to a high dose (20 and/or 40 µg/kg/min) dobutamine infusion (San Roman et al, 2003;Lu et al, 2001).…”